KRAS and neoplasm: The high precision/low sensitivity for KRAS indicated that a KRAS variant detected by the cfDNA-based NGS assay is likely present in the tumor tissue, although the absence of a KRAS variant in cfDNA does not necessarily imply a lack of KRAS mutations in tumor tissue.